-
Scientists from multiple countries jointly write an article to refute the theory of the origin of the new coronavirus laboratory
Time of Update: 2021-07-28
The paper reviewed a large number of published studies on the traceability of the new coronavirus and concluded that, like most viruses that can infect humans, the most direct explanation for the origin of the new coronavirus is from animals .
-
Experts say people with low immunity may need a third dose of vaccine
Time of Update: 2021-07-28
Hong Kong On the same day, Liu Zexing said when attending a radio program that studies have pointed out that the third dose of the new crown vaccine will increase the level of antibodies.
-
Health Commission: 14 new cases were confirmed on July 3, all imported from abroad
Time of Update: 2021-07-28
As of 24:00 on July 3, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 428 confirmed cases (including 8 severe cases), 86,783 cured and discharged cases, and 4,636 deaths.
-
Abnormal protein levels may help predict the risk of Alzheimer's disease
Time of Update: 2021-07-28
A new study conducted by American researchers found that the risk of Alzheimer's disease is related to abnormal levels of dozens of proteins in the blood, and this abnormality has begun to appear several years in advance .
-
The technological innovation of pharmaceutical excipients, the second generation of Suzhou capsule products detonated the market
Time of Update: 2021-07-28
Cheng Zhong said that in response to the transformation of China's pharmaceutical industry, the market's functional requirements for capsule excipients are constantly changing, and the original traditional gelatin capsules can no longer fully meet the needs of more diverse technologies .
-
100 drugs have been included in the "dual channel" catalog!
Time of Update: 2021-07-28
Medical insurance overall fund payment is settled on a monthly basis According to Jiangsu regulations, insured patients use "dual channel" management and separate payment of drugs to implement "three fixed" management, namely: Dingguotan medicine designated medical institutions, Dingguotan medicine designated retail pharmacies, and Dingguotan medicine medical insurance responsible physicians .
-
PHEXCOM successfully completed the audit of WuXi AppTec Suzhou GLP factory
Time of Update: 2021-07-28
On March 25-26, 2021, PHEXCOM audit expert Ms.
Zhang conducted an on-site audit of WuXi AppTec Suzhou Plant .
WuXi AppTec Suzhou was established in October 2006.
It is a wholly-owned subsidiary of WuXi AppTec.
-
Double antibody therapy is effective against new coronavirus mutant strains
Time of Update: 2021-07-28
American scientists wrote in the "Nature" magazine published on the 21st that their experiments on mice and hamsters showed that the combination therapy composed of two antibodies "strongly work together" is effective against a variety of (but not all) new coronavirus mutations.
-
Yabao Pharmaceutical's first Sino-US dual-reported drug, sorafenib tablets, was approved for listing
Time of Update: 2021-07-28
Recently, Yabao Pharmaceutical's 4 generic drug sorafenib tosylate tablets was officially approved for marketing.
The approval and registration of sorafenib tablets is the result of Yabao Pharmaceutical’s continuous high proportion of R&D investment entering the harvest period.
-
The vaccination rate continues to increase, and it will become easier and easier to deal with the virus
Time of Update: 2021-07-28
Zhang Wenhong said that "Delta" is currently the fastest virus in the world, but no matter how fast it runs, it is still a coronavirus and has not become a new virus.
Zhang Wenhong emphasized that this means that the original prevention and control measures against the virus are still effective, including vaccination .
-
Top ten pharmaceutical companies accelerate R&D strategy adjustment
Time of Update: 2021-07-28
Combination of investment transactions and asset divestiture activities in the first quarter In recent years, with the rapid development of innovative biotechnology companies, large global pharmaceutical companies have launched cooperation models such as acquisitions and investments to quickly supplement their new drug R&D pipelines .
-
How to prevent our country's head-on confrontation with "Delta"?
Time of Update: 2021-07-28
In addition, when it comes to the characteristics of the rapid spread of the "Delta" mutant strain, in fact, it mainly refers to the time from effective exposure and infection to the appearance of clinical symptoms and the speed of onset.
-
New pattern!
Time of Update: 2021-07-27
After the implementation of the policies of "separation of licenses and licenses" and "removal of distance between pharmacies", industry competition has intensified, and ordinary people have benefited, while life in small pharmacies has become even more difficult .
-
Wang Chen: The cold chain should be used as an important clue for the traceability of the new coronavirus
Time of Update: 2021-07-27
Epidemiology found that the cold chain is closely related to the spread of cases.
Some cold chain items have live viruses on the surface, making the chain of evidence more complete .
The cold chain should be regarded as an important traceability clue .
-
Incomplete inventory of sky-high drugs
Time of Update: 2021-07-27
The same benefits of drugs mean that the unit price is higher, and the pharmaceutical companies need corresponding regular returns to cover the continuous research and development costs .
Different from the high-priced drugs listed above, the currently approved cell therapy product indications cannot be regarded as rare diseases.
-
Zhong Nanshan: Dare to be a doctor
Time of Update: 2021-07-27
" Facing the flag, Chinese Academy of Engineering academician , director of the National Respiratory Disease Clinical Research Center, First Affiliated Hospital of Guangzhou Medical University, Zhong Nanshan solemn oath collar, two new developments in preparation of party members are Wuhan Take the form of remote video to solemnly swear .
-
A new anti-gout drug has exploded!
Time of Update: 2021-07-27
The fastest research and development is Hengrui Medicine's SHR4640 tablets, which is currently undergoing phase III clinical trials in China and is expected to become the first domestically approved Class 1 new drug in the field of anti-gout .
-
Health Commission: 12 newly diagnosed local cases in Jiangsu and Yunnan
Time of Update: 2021-07-27
As of 24:00 on July 21, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 638 confirmed cases (including 16 severe cases), 87,140 cured and discharged cases, and 4,636 deaths.
-
Two innovative drugs are planned to be included in the priority review from Betta Pharmaceuticals and Cinda Bio
Time of Update: 2021-07-27
Screenshot source: CDE official websiteAccording to the press release issued by Cinda Biologics, the drug's marketing application in mainland China is based on an open, single-arm, multi-center Phase 2 study, which aims to undergo at least first-line systemic treatment in the past To evaluate the efficacy and safety of pemigatinib in patients with locally advanced, recurrent or metastatic cholangiocarcinoma who have failed, unresectable surgery with FGFR2 fusion or rearrangement .
-
Zhou Hong, President of Roche Pharmaceuticals China, resigns to Merck's vice president of market access, Bian Xin, to take over
Time of Update: 2021-07-27
At the same time, Merck announced that Zhou Hong will serve as the head of Merck Group Pharmaceutical and Health China and international markets.